3 Auto Lighting Maker, Steel Towers and Pipes Maker and Injectables Pharmaceuticals Company Stocks With a Strong Future Roadmap: Varroc Engineering, Skipper and Strides Pharma Science
- November 19, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Varroc Engineering, Skipper and Strides Pharma Science: ROE of 14.3% to 17.9% and FY22 to FY26 revenue CAGR of 11.0% to 34.3%. Prices as of 18 Nov 2026.
Quick Answer
The three tail lamp, pylon and sterile injectable stocks to watch are Varroc Engineering, Skipper and Strides Pharma Science. Their return on equity ranges from 14.3% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.0% to 34.3%. Strides Pharma Science has the highest return on equity at 17.9%, while Skipper has the fastest revenue growth at 34.3% a year. Prices are based on the 18 November 2026 close, and this article is educational, not investment advice.
Tail lamp, pylon and sterile injectable stocks give investors a way to track businesses that sit close to everyday demand in India. Varroc Engineering, Skipper and Strides Pharma Science cover an auto lighting maker, a steel towers and pipes maker and an injectables pharmaceuticals company.
This list covers three tail lamp, pylon and sterile injectable stocks with complete current figures: Varroc Engineering, Skipper and Strides Pharma Science. Every figure comes from the latest reported financials and the 18 November 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Tail Lamp, Pylon and Sterile Injectable Stocks?
Tail lamp, pylon and sterile injectable stocks are listed companies that make lighting, electronics and polymer parts for vehicles, make steel towers and polymer pipes for power and water projects, and make injectable and oral medicines for global markets. Their earnings depend on vehicle output, grid and water projects and medicine orders.
Tail Lamp, Pylon and Sterile Injectable Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Varroc Engineering | 821.8 | 12,256 | 61.2 | 36.9 | 14.3 | 0.52 |
| Skipper | 481 | 5,800 | 25.8 | 44.4 | 14.3 | 0.64 |
| Strides Pharma Science | 958.1 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
On valuation, Skipper and Strides Pharma Science trade at a P/E below the industry P/E, while Varroc Engineering trades above it, which reflects the growth the market already expects. Readers comparing tail lamp, pylon and sterile injectable stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in tail lamp, pylon and sterile injectable stocks can use the coming numbers to test whether growth is holding.
Why Do Tail Lamp, Pylon and Sterile Injectable Stocks Have a Strong Roadmap in India?
Tail lamp, pylon and sterile injectable stocks have a strong roadmap in India because wider use of electronics in vehicles, large grid and water projects and steady demand for medicines keep widening the market for these companies.
- Auto lighting. New vehicles carry advanced lamps.
- Towers and pipes. Grids and cities need steel and polymer lines.
- Injectables. Hospitals need sterile medicines.
Why Varroc Engineering Features Among These Tail Lamp, Pylon and Sterile Injectable Stocks
Among the tail lamp, pylon and sterile injectable stocks on this list, Varroc Engineering is a Maharashtra-based automotive component maker with a focus on exterior lighting systems, electrical and electronic parts and polymer products for two-wheeler, passenger car and commercial vehicle makers across the world.
The company has a return on equity of 14.3%, a debt to equity ratio of 0.52 and a market capitalisation of Rs 12,256 crore. The stock trades at a P/E of 61.2, above the industry P/E of 36.9.
Revenue rose from Rs 5,878 crore in FY22 to Rs 8,917 crore in FY26, a compound annual growth rate of 11.0%. Net profit for FY26 was Rs 230 crore, a net margin of 2.6%. In the June 2026 quarter, revenue grew 29.9% year on year to Rs 2,640 crore.
Roadmap: The company is growing its lighting business with advanced LED products and increasing content per vehicle in India and overseas. Orders from vehicle makers, including electric vehicle programmes, give visibility on future volumes.
What to watch: Monitor order wins in lighting and the growth of content per vehicle.
Why Skipper Features Among These Tail Lamp, Pylon and Sterile Injectable Stocks
Among the vehicle lighting, steel towers and hospital drug shares on this list, Skipper is a Kolkata-based maker of power transmission towers and poles and of polymer pipes and fittings, and it also takes on infrastructure projects in India and overseas.
Revenue rose from Rs 1,711 crore in FY22 to Rs 5,563 crore in FY26, a compound annual growth rate of 34.3%. Net profit grew from Rs 25.1 crore in FY22 to Rs 213 crore in FY26, which works out to a compound annual growth rate of 70.6%.
In the June 2026 quarter, revenue grew 4.5% year on year to Rs 1,314 crore, while net profit rose 25.5% to Rs 56.8 crore. The company has a return on equity of 14.3%, a debt to equity ratio of 0.64 and a market capitalisation of Rs 5,800 crore. The stock trades at a P/E of 25.8, below the industry P/E of 44.4.
Roadmap: The company is growing its transmission tower order book and adding polymer pipe capacity, which spreads its earnings across power and water related demand. Grid expansion and housing spending support both businesses.
What to watch: Track tower order inflows, pipe volumes and progress on new capacity.
Why Strides Pharma Science Features Among These Tail Lamp, Pylon and Sterile Injectable Stocks
Among the three companies on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%.
Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Varroc Engineering vs Skipper vs Strides Pharma Science on Key Financials
The table below sets the three tail lamp, pylon and sterile injectable stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Varroc Engineering | 5,878 | 8,917 | 11.0% | 230 | 2.6% |
| Skipper | 1,711 | 5,563 | 34.3% | 213 | 3.8% |
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
Strides Pharma Science posts the highest return on equity in this group at 17.9%. Varroc Engineering has the largest FY26 revenue at Rs 8,917 crore, and Skipper shows the fastest revenue growth with a 34.3% compound annual rate. A useful habit with tail lamp, pylon and sterile injectable stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Varroc Engineering | 2,033 | 2,640 | 29.9% |
| Skipper | 1,257 | 1,314 | 4.5% |
| Strides Pharma Science | 1,128 | 1,270 | 12.6% |
Key Risks to Check Before Investing in Tail Lamp, Pylon and Sterile Injectable Stocks
Every theme carries risks that deserve a check before any decision. For these tail lamp, pylon and sterile injectable stocks, the main points are: Long-term vehicle lighting, steel towers and hospital drug shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Demand cycles. Sales can vary with seasons and rates.
- Government spending. Public project funding can shift between periods.
- Regulatory approvals. Plant inspections and approvals can affect supplies.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter tail lamp, pylon and sterile injectable stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Tail Lamp, Pylon and Sterile Injectable Stocks
Tail lamp, pylon and sterile injectable stocks work best when investors track growth, valuation and return on equity side by side. Varroc Engineering, Skipper and Strides Pharma Science each have a clear plan to grow. Based on the 18 November 2026 close, Varroc Engineering trades at Rs 821.8, Skipper at Rs 481 and Strides Pharma Science at Rs 958.1. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these tail lamp, pylon and sterile injectable stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track tail lamp, pylon and sterile injectable stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are tail lamp, pylon and sterile injectable stocks?
Ans. Tail lamp, pylon and sterile injectable stocks are listed companies that make lighting, electronics and polymer parts for vehicles, make steel towers and polymer pipes for power and water projects, and make injectable and oral medicines for global markets. Their earnings depend on vehicle output, grid and water projects and medicine orders. This list looks at three of them, Varroc Engineering, Skipper and Strides Pharma Science, using reported FY22 to FY26 financials and the 18 November 2026 closing prices.
Which tail lamp, pylon and sterile injectable stocks are covered in this list?
Ans. This list covers Varroc Engineering, Skipper and Strides Pharma Science. Based on the 18 November 2026 close, Varroc Engineering traded at Rs 821.8, Skipper at Rs 481 and Strides Pharma Science at Rs 958.1. Their return on equity ranges from 14.3% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 11.0% to 34.3%.
Why do tail lamp, pylon and sterile injectable stocks have a strong future roadmap in India?
Ans. Tail lamp, pylon and sterile injectable stocks have a strong roadmap in India because wider use of electronics in vehicles, large grid and water projects and steady demand for medicines keep widening the market for these companies. The main drivers are as follows. Auto lighting. New vehicles carry advanced lamps. Towers and pipes. Grids and cities need steel and polymer lines. Injectables. Hospitals need sterile medicines. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Varroc Engineering performed financially?
Ans. Revenue rose from Rs 5,878 crore in FY22 to Rs 8,917 crore in FY26, a compound annual growth rate of 11.0%. Net profit for FY26 was Rs 230 crore, a net margin of 2.6%. In the June 2026 quarter, revenue grew 29.9% year on year to Rs 2,640 crore. The company has a return on equity of 14.3%, a debt to equity ratio of 0.52 and a market capitalisation of Rs 12,256 crore. The stock trades at a P/E of 61.2, above the industry P/E of 36.9. Looking ahead, the company is growing its lighting business with advanced LED products and increasing content per vehicle in India and overseas. Orders from vehicle makers, including electric vehicle programmes, give visibility on future volumes.
How has Skipper performed financially?
Ans. Revenue rose from Rs 1,711 crore in FY22 to Rs 5,563 crore in FY26, a compound annual growth rate of 34.3%. Net profit grew from Rs 25.1 crore in FY22 to Rs 213 crore in FY26, which works out to a compound annual growth rate of 70.6%. In the June 2026 quarter, revenue grew 4.5% year on year to Rs 1,314 crore, while net profit rose 25.5% to Rs 56.8 crore. The company has a return on equity of 14.3%, a debt to equity ratio of 0.64 and a market capitalisation of Rs 5,800 crore. The stock trades at a P/E of 25.8, below the industry P/E of 44.4. Looking ahead, the company is growing its transmission tower order book and adding polymer pipe capacity, which spreads its earnings across power and water related demand. Grid expansion and housing spending support both businesses.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What risks should investors check before buying tail lamp, pylon and sterile injectable stocks?
Ans. Investors should check a few risks before buying tail lamp, pylon and sterile injectable stocks. Demand cycles. Sales can vary with seasons and rates. Government spending. Public project funding can shift between periods. Regulatory approvals. Plant inspections and approvals can affect supplies. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of tail lamp, pylon and sterile injectable stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 18 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.